E

eMed

AI-driven platform for employer GLP-1 management

Revenue Operations Manager

Full-Time
No salary listed
Senior
Bachelor's
Miami, FL, USA
In Person
Sales & Account ManagementSales Operations

About the job

Requirements
  • At least 5 years of experience in revenue operations, marketing operations, or sales operations, with direct ownership of lead management and/or channel operations.
  • Hands-on Salesforce fluency, including lead and opportunity objects, routing and assignment, campaigns, reports, and dashboards.
  • Experience with marketing automation platforms and lead-routing or enrichment tools.
  • Ability to build processes where none exist and drive adoption across sales, marketing, and partner teams.
  • Ability to define funnel metrics and build reporting to track them.
  • Bachelor's degree in Business, Marketing, or a related field, or equivalent experience.
Responsibilities
  • Own core sales process standards, including opportunity hygiene, stage definitions and exit criteria, required fields, and pipeline governance across pods and segments.
  • Analyze market data to build equitable sales area responsibilities and recommend incentive compensation plans aligned with company revenue targets.
  • Run the operational cadence behind pipeline reviews and forecasting, partnering with the Data & Analytics Analyst on reporting.
  • Build top-of-funnel operations end to end, including lead capture, enrichment, scoring, routing, service-level agreements, and conversion to opportunity.
  • Partner with Marketing to operationalize campaigns with clean source and attribution data, and build campaign-to-pipeline visibility for go-to-market leadership.
  • Own channel and partner referral operations from referral intake through Salesforce opportunity creation and attribution, establishing a single source of truth and eliminating double-counting risk in leadership reporting.
  • Author and maintain the Revenue Operations policy guide covering lead ownership, routing logic, rules of engagement, referral attribution, sales crediting, and service-level agreement standards; keep it current as processes evolve.
  • Arbitrate exceptions and ownership disputes against documented policy, and drive adoption of policy changes across the field.
  • Serve as the operational bridge between direct sales pods, business development representatives, Marketing, Channel, Sales, and Customer Success to ensure every team follows a common, documented process.
  • Maintain revenue data hygiene standards for duplicates, sources, close dates, and amounts in partnership with the Salesforce team.
  • Measure funnel and process health, including conversion, velocity, coverage, and source mix, and recommend data-grounded improvements.
Desired Qualifications
  • B2B healthcare, benefits, or digital health experience.

About the company

eMed operates a digital health platform that enables employer-sponsored GLP-1 weight-management programs by providing remote diagnostics, clinician-prescribed medications, and adherence coaching. Its Empathetic AI engages members, tracks biomarkers, and coordinates medical oversight with medication access and coaching under a subscription-based capitation model that covers population health management. Unlike typical programs, it tightly links access to meds with ongoing adherence through an agentic AI and structured clinical support, while shifting financial risk to employers. Its goal is to reduce health costs for employers and payers while delivering meaningful weight-management and chronic-care improvements at scale.

Company Size

201-500

Company Stage

Series A

Total Funding

$200M

Headquarters

Miami, Florida

Founded

2020

Get referred to eMed

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CVS Caremark partnership opened employer-subsidized GLP-1 access in February 2026.
  • Tom Brady's January 2026 role keeps eMed visible to employers and workers.
  • March 2026 capital funds a capitated model, expanding enterprise sales capacity.

What critics are saying

  • Hims, Ro, CVS Caremark, and Alight compress eMed's pricing power immediately.
  • If Novo Nordisk and Eli Lilly lower GLP-1 list prices, eMed's savings story collapses.
  • If employers treat GLP-1s as a commodity benefit, eMed becomes a thin referral layer.

What makes eMed unique

  • March 26, 2026 funding valued eMed above $2 billion, signaling category leadership.
  • August 11, 2026 Alight added eMed to its employer GLP-1 partner network.
  • eMed's Empathetic AI pairs remote diagnostics, prescribing, and adherence coaching in one workflow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Paid Vacation
  • Paid Holidays
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Training Programs
  • Meal Benefits
  • Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

0%
PR Newswire
Oct 19th, 2026
eMed Population Health appoints Marisstella Marinkovic as Chief Communications Officer.

eMed Population Health appoints Marisstella Marinkovic as Chief Communications Officer. Oct 19, 2026, 08:34 ET MIAMI, Oct. 19, 2026 /PRNewswire/ - eMed Population Health today announced the appointment of Marisstella Marinkovic as Chief Communications Officer (CCO). A transformational executive with more than 20 years of experience building iconic brands, shaping corporate narratives, and driving business growth, Marinkovic will help accelerate eMed's next phase of growth and strengthen its position as a leader in population health. As Chief Communications Officer, Marinkovic will lead communications and accelerate the company's unprecedented growth with clients and partners. She will oversee strategic storytelling, executive communications, stakeholder engagement, and social media, including all of eMed's social channels. "eMed is the definitive employer platform for GLP-1 care, and our momentum is real. We're expanding into new markets, and the results speak for themselves. Now the world needs to hear it," said Linda Yaccarino, Chief Executive Officer of eMed Population Health. "Marisstella's focus will be to elevate eMed's profile as a category-defining company, ensuring our leadership and innovation continue to shape the future of population health." Previously, Marinkovic was Chief Marketing Officer for Nissan U.S., where she oversaw communications, media, customer experience and data-driven innovation. Most recently, she led an AI-powered transformation of marketing and revenue strategy at Wilshire Law Firm. Her work has earned some of the industry's top honors, including Cannes Lions and Effie Awards. "eMed's mission is deeply personal to me," said Marinkovic. "Through my own health journey, I've seen how important access, education and support can be in helping people take control of their health. I'm especially passionate about advancing women's health and the role technology can play in removing barriers to care. I'm excited to join a company that's using technology to empower people to take charge of their health." Marinkovic joined eMed on October 12 and serves on the executive leadership team, reporting directly to CEO Linda Yaccarino. About eMed Population Health eMed Population Health is transforming healthcare through technology-enabled solutions that expand access, improve outcomes, and empower individuals to take control of their health. By combining telehealth, diagnostics, care navigation, and population health capabilities, eMed delivers scalable solutions that help consumers, employers, payers, and healthcare organizations improve health outcomes while reducing barriers to care. SOURCE eMed Population Health

HealthTech HotSpot
Aug 11th, 2026
Alight and eMed join forces to expand access to GLP-1 therapies for employers, advancing population and workforce health.

Alight and eMed join forces to expand access to GLP-1 therapies for employers, advancing population and workforce health. DEERFIELD, Ill.-(BUSINESS WIRE)-Alight, Inc. (NYSE: ALIT), a leading benefits administration provider of health, wealth and leave solutions, today announced the addition of eMed Population Health, Inc., a platform for employer-sponsored preventative health management, to the Alight Partner Network. The collaboration will enhance employer-sponsored access to GLP-1 therapies and give organizations a scalable way to support eligible employees, improve adherence to treatment and address the cost and complexity of weight management benefits. The groundswell of interest in GLP-1 medications among the general population has soared in recent years - 11% of U.S. adults now take GLP-1 medications for weight loss, up from 3% in 2024, according to Gallup's National Health and Well-Being Index. As demand for obesity and chronic condition management continues to rise, employers are seeking solutions that foster long-term workforce health while helping manage healthcare costs. By adding eMed to its Partner Network, Alight is expanding its health ecosystem with an industry-leading, flexible, outcomes-focused GLP-1 solution designed to support employers across a range of workforce health goals, benefits strategies and coverage approaches. Through a connected experience that includes clinical evaluation, treatment access, adherence support and ongoing engagement, organizations can provide eligible employees with personalized care, regardless of their coverage needs, while gaining greater visibility into utilization and outcomes. "Employers are looking for smarter, more sustainable ways to address rising healthcare costs while improving outcomes for their people," said Jessica Borchik, SVP, Partner Strategy and Sales at Alight. "By welcoming eMed into our Partner Network, we're expanding access to a clinically rigorous, outcomes-focused approach to GLP-1 management that helps organizations support employee health while maintaining cost control." The collaboration reflects a shared commitment to helping employers, including Fortune 500 companies already supported by Alight, implement GLP-1 programs that align with their unique needs while improving health outcomes and managing costs. "We're at a pivotal moment in healthcare where employers have an opportunity to fundamentally change the trajectory of population health and chronic diseases," said Greg Page, SVP Partnerships & Strategy at eMed. "By partnering with Alight, we're combining access and accountability in a way that helps organizations improve employee health, manage costs, and realize the full promise of GLP-1 therapies." Together, Alight and eMed will provide employers with a scalable way to manage utilization, improve adherence and reduce avoidable healthcare spend while delivering a more connected and personalized health experience for eligible employees. About Alight Solutions Alight is a leading benefits administration provider of health, wealth, leave and point solutions for many of the world's largest organizations and over 30 million people. Through the administration of employee benefits, Alight helps clients gain a benefits advantage while building a health and financially secure workforce by unifying the benefits ecosystem across health, wealth, wellbeing, absence management and navigation. Its Alight Worklife(R) platform empowers employers to gain a deeper understanding of their workforce and engage them throughout life's most important moments with personalized benefits management and data-driven insights, leading to increased employee wellbeing, engagement and productivity. Learn more at alight.com. About eMed eMed is the world's first end-to-end GLP-1 care platform built on Empathetic AI(TM). From remote diagnostics and clinician-led prescriptions to adherence coaching and insights, eMed empowers employers to manage population health with accountability and compassion. Learn more at www.eMed.com.

Fox Business
Jul 15th, 2026
Tom Brady joins eMed as chief wellness officer to expand employer-covered GLP-1 weight loss access

NFL legend Tom Brady has partnered with digital health company eMed as chief wellness officer to expand access to GLP-1 weight loss medications. The collaboration aims to incentivise employers to cover these drugs for eligible workers whilst reducing health insurance claims. Brady said the partnership addresses America's obesity epidemic by "democratising health and wellness in a way that the world has never seen". With more than 60% of Americans receiving health benefits through employers, eMed targets companies to provide coverage for GLP-1 medications. eMed CEO Linda Yaccarino called GLP-1 drugs a "pharmaceutical revolution", noting the programme combines AI, technology, and clinical support. The initiative offers both health benefits for employees and financial advantages for employers covering the medications.

MobiHealthNews
Jul 7th, 2026
Crux, eMed partner to expand employer access to GLP-1 medications.

Crux, eMed partner to expand employer access to GLP-1 medications. The collaboration aims to help employees access FDA-approved GLP-1s alongside clinical care, prescribing support, and payment and pharmacy fulfillment. Specialty employee benefits platform Crux announced a strategic collaboration with telehealth and digital health company eMed to improve employees' access to GLP-1 medications. Miami-based eMed, whose founding chief wellness officer is former NFL quarterback Tom Brady, offers an individual and employee health benefit platform that provides access to GLP-1 medications, at-home blood testing and a care package for common side effects of GLP-1s. Crux works with employers, individuals, brokers and consultants to offer benefits packages aimed at improving individuals' access to medication, including pharmacy fulfillment and home delivery. The partnership will combine eMed's clinical care model, including clinician evaluation and prescribing support, with Crux's payment and fulfillment infrastructure, which facilitates employers' tax-advantaged health reimbursement arrangement (HRA) contributions for employees, to help them access prescriptions, including FDA-approved GLP-1 medications. Members will have access to continuous clinical support through eMed, including dose adjustments, coaching and regular check-ins. "This partnership represents a pivotal step toward a future where healthcare is no longer reactive, but continuous, proactive and deeply personal," eMed CEO Linda Yaccarino said in a statement. "While GLP-1s are a powerful catalyst, they open the door to reimagining how clinical care, technology and benefits converge to drive better outcomes at scale. Together with Crux, we're enabling employers to lead that transformation while empowering people to take greater control of their health and their future." THE LARGER TREND Earlier this year, eMed closed a $200 million Series A funding round at a more than $2 billion valuation. In August 2025, the company's CEO, Yaccarino, joined eMed after serving for two years as CEO of Elon Musk-owned social media platform X, formerly Twitter. Prior to X, Yaccarino served as an NBCUniversal ad sales executive. A month later, X's former global head of strategic partners, Amy Elkins, joined eMed as chief operating officer. eMed announced a partnership with Arianna Huffington's behavioral-change technology platform, Thrive Global, to offer an end-to-end obesity-care program for employers. The offering combined eMed's clinical platform for GLP-1 and GIP medications with Thrive's behavior change and lifestyle offerings. eMed first launched in the fall of 2020 as a digital health company focused on at-home rapid COVID-19 testing through a collaboration with pharma giant Abbott. The company subsequently offered Urgent Care Telehealth Kits for at-home testing of COVID, influenza, strep throat and urinary tract infections, and has since pivoted to become a GLP-1-focused and AI-enabled weight-management platform.

Yahoo Finance
May 11th, 2026
Linda Yaccarino reflects on X transformation: 'I couldn't have been prouder

Linda Yaccarino, now CEO of telehealth company eMed, has reflected on her tenure leading Elon Musk's X, which ended in July 2025 after two years. She described the role as requiring conviction and comfort with being alone during a "massive global transformation under scrutiny". Yaccarino, who previously led global advertising at NBC Universal, was hired by Musk in May 2023 to stabilise the troubled social media platform. She credited her team with modernising business operations, expanding video features and digital wallet services, and bringing back advertisers. "I couldn't have been prouder," Yaccarino said, citing the company's financial stability and profitability. She joined eMed, a GLP-1 weight-loss medication and telehealth provider, in August 2025, applying her digital revenue expertise to healthcare.